Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals is viewed as a fundamentally strong RNAi leader because its strong intellectual property, modular drug-development engine, and repeated execution have produced a validated commercial portfolio across rare and cardiometabolic diseases, with four drugs already on the market in 2026 and Leqvio plus Qfitlia extending reach through partners. The company’s growth case is anchored by Amvuttra’s expanding TTR franchise, where management reiterated $4.2 billion to $4.5 billion in total TTR revenue, while >2,000 new prescribers, ~80% untreated TTR-CM patients, and a ~25% total topline CAGR ambition through 2030 support a durable runway. Beyond current sales, the pipeline adds meaningful optionality and margin expansion through nucresiran, brezosiran, mivelsiran, and zilebesiran, with multiple late-stage and mid-stage catalysts that could deepen Alnylam’s platform value and sustain profitability.

Alnylam Pharmaceuticals is facing a weakening near-term fundamental setup as management sees no 4Q demand acceleration, with FY TTR revenue tracking toward the low end of the $4.2B-$4.4B range and FY27 guidance delayed until February to assess 340B reform. New UnitedHealthcare Medicare Advantage restrictions starting October 1 could delay first-line Amvuttra starts for about 10% of patients, while the complete sales-force expansion has not yet translated into stronger physician engagement or new patient growth. Although Q3 Amvuttra revenue of $1.13B was in line, it included a $17M inventory benefit and a one-time $10M Medicaid net price benefit, and the company’s reduced FY27 sales outlook and lower peak estimate underscore limited visibility into sustainable growth.